Anecita P Fadol1, Elie Mouhayar2, Cielito C Reyes-Gibby3. 1. Department of Nursing, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0456, Houston, TX 77030, afadol@mdanderson.org. 2. Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1451, Houston, TX 77030, emouhayar@mdanderson.org. 3. Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1468, Houston, TX 77030-4009, creyes@mdanderson.org.
Abstract
OBJECTIVES: Investigate the use of cardiac resynchronization therapy (CRT) in cancer patients with heart failure (HF); assess factors associated with ischemic and non-ischemic HF. BACKGROUND: Many newer cancer therapies are cardiotoxic; thus, the incidence of HF has been increasing in this high-risk patient population. CRT has beneficial effects on morbidity, mortality, and left ventricular function in patients with non-ischemic cardiomyopathy, yet cancer patients and survivors who develop severe HF and are eligible for CRT often do not receive it. METHODS: Review of 2 years of echocardiography and electrocardiography data from cancer patients. RESULTS: Of 272 patients meeting inclusion criteria for CRT placement (LVEF ≤35%, QRS duration ≥120 ms), 131 (48.2%) had HF with ischemic etiology and 141 (51.8%) had HF with non-ischemic etiology. Most patients had solid tumors, including breast, lung, sarcoma, and lymphoma (73.2%, n=199). Only 21.3% (58/272; 27 ischemic; 31 non-ischemic) underwent CRT placement, who were mostly women and those with solid tumors. Non-ischemic HF was significantly associated with younger age (<65 years) (OR=0.91; 95% CI=0.87-0.95) and female sex (OR=2.5; 95% CI=1.1-6.0). As expected, ischemic HF was significantly associated with history of myocardial infarction, diabetes, and cardiovascular disease. CONCLUSIONS: CRT is underutilized in cancer patients with HF. Most of the cancer patients who did not receive CRT had non-ischemic HF secondary to chemotherapy. CRT may be less utilized in those patients due to shortened life expectancy, yet evidence suggests that CRT has beneficial effects on morbidity, mortality, and left ventricular function. Its use may improve patient quality of life and allow oncologists to continue cancer treatments that could prolong survival.
OBJECTIVES: Investigate the use of cardiac resynchronization therapy (CRT) in cancer patients with heart failure (HF); assess factors associated with ischemic and non-ischemic HF. BACKGROUND: Many newer cancer therapies are cardiotoxic; thus, the incidence of HF has been increasing in this high-risk patient population. CRT has beneficial effects on morbidity, mortality, and left ventricular function in patients with non-ischemic cardiomyopathy, yet cancer patients and survivors who develop severe HF and are eligible for CRT often do not receive it. METHODS: Review of 2 years of echocardiography and electrocardiography data from cancer patients. RESULTS: Of 272 patients meeting inclusion criteria for CRT placement (LVEF ≤35%, QRS duration ≥120 ms), 131 (48.2%) had HF with ischemic etiology and 141 (51.8%) had HF with non-ischemic etiology. Most patients had solid tumors, including breast, lung, sarcoma, and lymphoma (73.2%, n=199). Only 21.3% (58/272; 27 ischemic; 31 non-ischemic) underwent CRT placement, who were mostly women and those with solid tumors. Non-ischemic HF was significantly associated with younger age (<65 years) (OR=0.91; 95% CI=0.87-0.95) and female sex (OR=2.5; 95% CI=1.1-6.0). As expected, ischemic HF was significantly associated with history of myocardial infarction, diabetes, and cardiovascular disease. CONCLUSIONS: CRT is underutilized in cancer patients with HF. Most of the cancer patients who did not receive CRT had non-ischemic HF secondary to chemotherapy. CRT may be less utilized in those patients due to shortened life expectancy, yet evidence suggests that CRT has beneficial effects on morbidity, mortality, and left ventricular function. Its use may improve patient quality of life and allow oncologists to continue cancer treatments that could prolong survival.
Authors: M A Konstam; R D Patten; I Thomas; T Ramahi; K La Bresh; S Goldman; W Lewis; A Gradman; K S Self; V Bittner; W Rand; D Kinan; J J Smith; T Ford; R Segal; J E Udelson Journal: Am Heart J Date: 2000-06 Impact factor: 4.749
Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245
Authors: D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia Journal: Ann Intern Med Date: 1979-11 Impact factor: 25.391
Authors: Inder S Anand; Peter Carson; Elizabeth Galle; Rui Song; John Boehmer; Jalal K Ghali; Brian Jaski; JoAnn Lindenfeld; Christopher O'Connor; Jonathan S Steinberg; Jill Leigh; Patrick Yong; Michael R Kosorok; Arthur M Feldman; David DeMets; Michael R Bristow Journal: Circulation Date: 2009-02-09 Impact factor: 29.690
Authors: E Arbustini; G Merlini; A Gavazzi; M Grasso; M Diegoli; R Fasani; V Bellotti; G Marinone; P Morbini; B Dal Bello Journal: Am Heart J Date: 1995-09 Impact factor: 4.749
Authors: Tammy F Chu; Maria A Rupnick; Risto Kerkela; Susan M Dallabrida; David Zurakowski; Lisa Nguyen; Kathleen Woulfe; Elke Pravda; Flavia Cassiola; Jayesh Desai; Suzanne George; Jeffrey A Morgan; David M Harris; Nesreen S Ismail; Jey-Hsin Chen; Frederick J Schoen; Annick D Van den Abbeele; George D Demetri; Thomas Force; Ming Hui Chen Journal: Lancet Date: 2007-12-15 Impact factor: 79.321